Cancer cell lines are essential for functional studies of cancer. When explanted tumors are grown in vitro, however, non-cancer fibroblasts paradoxically overgrow the malignant cells. Here we report production of a series of immunodeficient hprt-null mice. When human tumors are expanded in these mice, the resultant tumor is composed of human cancer cells and biochemically defective mouse stromal cells. When these tumors are explanted into culture and grown in HAT media, human cancer cell lines can be readily isolated. We demonstrate proof-of-principle of the mice for personalized cell line isolation and chemosensitivity testing. This approach may be used to guide chemotherapy selection in the future.
Introduction
Selecting the most appropriate chemotherapy for a given patient has historically been based on histopathology and past studies demonstrating that specific drugs are generally active against that malignancy. However, drugs deemed active against a particular type of cancer, are most commonly active in only a subset of patients with those cancers. Further, chemotherapeutic agents are generally more toxic and expensive than most other medications in widespread use. Accordingly, an alternative strategy is to test functionally whether a given patient's cancer is likely or not to respond to specific drugs. In vitro chemotherapy sensitivity and resistance assays (CSRAs), a natural extrapolation of antimicrobial susceptibility testing, was first reported in 1957 (1) . Some 50 years later, however, the official position of the American Society of Clinical Oncology has been that this type of testing is still not ready for routine clinical use (2) .
Problems with CSRA include the many different formats for this testing (2) , and results from clinical trials, comparing CSRA guided therapy to conventional treatment, have varied from no significant difference to highly significant benefit (3) . Finally, most groups test cancer cells immediately after resection, and these may be sick or dying from hypoxia, anesthetic drugs, or overnight shipping, and so any toxicity to these cells may reflect synergistic toxicity of the drugs tested with any of these effects.
We hypothesize that low-passage cell lines might better represent their respective tumors and therefore more accurately predict in vivo chemosensitivity. Isolating cancer cell lines, however, can, counterintuitively, be difficult, especially from solid primary tumors (4) . To date, the success rate for the generation of cell lines is only 10-40% for many solid tumors (4) (5) (6) (7) (8) . The most significant barrier to routine cancer cell line production is that when tumors are explanted into tissue culture, fibroblasts and other stromal cells proliferate, overgrow and eliminate the malignant cells.
We report production of nude-, SCID-(severe combined immunodeficiency) and NSG-(Non obese diabetic [NOD] , SCID, Interleukin-2 receptor Gamma [IL2Rγ]), hprtnull mice. During growth of implanted human cancers in these mice, biochemically defective mouse stromal cells replace the human stromal cells from the original tumor (9, 10) . After explanting these xenografts into culture, mouse cells can be eliminated by selection in hypoxanthine, aminopterin, and thymidine (HAT) containing media (11, 12) to isolate pure human cancer cells. Using this system, we isolated a total of 6 pancreatic ductal adenocarcinoma (PDA) cell lines and one ovarian cancer cell line. One of the PDA cell lines was isolated from the corresponding surgically resected sample and tested for in vitro chemosensitivity using a 3,131-drug panel (13) . In comparison to other PDA cell lines, this cell line in vitro was differentially more sensitive to digitoxin and nogalamycin, which correlated with in vivo response in mice, where the same two drugs demonstrated selective activity against xenografted tumors. These data suggest a possible novel paradigm for functional personalized chemotherapeutic selection by isolating lowpassage cancer cell lines and screening them with large drug panels.
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Patient samples and xenografting
Primary tumors from patient-derived resection specimens or xenografts from standard nude mice were harvested with informed consent and IRB approval. They were implanted in anesthetized standard B6 nude and hprt-null B6 nude mice. Following a small skin incision, a 5mm 3 sample coated with Matrigel Matrix (BD Biosciences, Bedford, MA) was implanted subcutaneously in each upper flank, the incision was closed using staples, and the site was disinfected with Betadine (Purdue Frederick, Stamford, CT). Among the 6 pancreatic cancers, 3 were selected because they were familial, and 3 because they have undergone full exomic DNA sequencing as xenografted samples (14) .
Tumor harvest and culture When tumors reached approximately 1 cm in diameter, mice were sacrificed, and tumors harvested. In a laminar flow biosafety cabinet, tumors were finely minced and incubated in DMEM containing 750 units/ml of type IV collagenase (Invitrogen) and 500 units/ml of hyaluronidase (Sigma-Aldrich Inc., St. Louis, MO) for 1 hour at 37°C, and pipetting up and down 20 times to mechanically fragment the tumor. The cell solution was plated at 0.5, 1 and 2 mls per well on 6-well plates coated with or without type I rat tail collagen (BD Biosciences) in MEM with 20% fetal bovine serum, supplemented with standard concentrations of penicillin/streptomycin, L-glutamine, 5 ng/ml of human recombinant EGF (all Invitrogen) and 0.2 U/ml of human insulin (Sigma-Aldrich).
Following two days recovery (designated day 0), 1X HAT (100uM sodium hypoxanthine, 400nM aminopterin, 16nM thymidine, Invitrogen) media was fed to half of the cultures. (Fig. 1A) . To confirm genotyping (Fig. 1B, Supplementary Fig. S3 ), we harvested tail cuttings from mice II and III (Fig. 1A) , trypsinized them and grew the cells in tissue culture. These samples were grown in the presence of HAT or 6-thioguanine (6TG) to select for or against HPRT function, respectively (Fig. 1C) . As predicted from their genotype ( Patient-specific cancer cell line production A PDA xenograft (Panc410) was implanted into these mice and the tumors were harvested for cell culture. After plating and 2 days of recovery, cultures of Panc410 (Day 0) showed a mixture of cancer cells clustering together to form "islands", and scattered fibroblasts and other stromal cells ( Fig. 2A and 2D ). Cultures explanted from the hprtnull mouse and treated with HAT selection media typically yielded fibroblast free cancer cell lines after 2-3 weeks ( Fig. 2A-C Cancer Cell Line Isolating Tools 11 fibroblasts and other stromal cells, allowing for the small cancer cell "islands" to expand and eventually coalesce. In contrast, a sister culture, grown in the absence of HAT, was heavily contaminated with fibroblasts ( Fig. 2D-F) . These stromal cells surrounded cancer cell islands (Fig. 2E), overgrew them (Fig. 2F) , and precluded producing cancer cell lines from these cultures. The resultant cell line matched the patient's microsatelllites and was tumorigenic in nude mice. To confirm its epithelial origin, the cell line was stained for cytokeratin and smooth muscle actin, which stained positive and negative respectively, as expected (data not shown).
Chemosensitivity-Initial Screen
One potential application of rapid cell line isolation is personalized chemosensitivity testing. To demonstrate utility of the mice for this purpose, we first implanted SCID hprt-null mice with a surgically resected PDA and isolated the cell line Panc502 (Supplementary Fig. S4 ). We then screened this cell line against the JHDL (13) consisting of 3,131 drugs ( Supplementary Fig. S5 ). The library includes 1,907 US FDA approved drugs, 570 drugs approved for clinical use in other countries and 654 other drugs in various phases of development. A histogram of the number of drugs, graphed as a function of the percent growth inhibition (Fig. 3A) , showed that most drugs fit under a Gaussian distribution (mean 5.0%, SD 11.8%), which we interpreted as inactive drugs for this cancer cell line. The mean plus or minus 3 standard deviations encompasses 2817 drugs, or ~90% of those tested. More importantly, 314 drugs (~10%) showed activity above the normal distribution, and these were considered potentially active drugs 
approved and 12 drugs previously approved, but currently discontinued (combined ~2.8%
of drugs in the library).
The FDA approved drug, digoxin, showed 95% growth inhibition, consistent with its recent discovery as a potential anti-tumor agent (15) . We also identified two terpenoid drugs, pristimerin and triptonide, isolated from Chinese medicinal plants, as potent inhibitors of growth (16) (17) (18) . Among the 125 antineoplastic drugs tested (Supplementary Table 2 ), only a third (49 drugs, 39.2%) showed activity above the bell-shaped curve.
Nine drugs demonstrated greater than 99% growth inhibition, including 7 nucleic acidtargeting chemotherapeutics (actinomycin C, actinomycin D, chromomycin A3, camptothecin, doxorubicin, gemcitabine, and mitoxantrone) and 2 terpenoid natural products (pristimerin and triptonide).
Novel drugs with activity against PDA From the drugs demonstrating 75% or higher inhibition at 10μM final concentration, we selected 10 drugs to study further (Table 1) , after excluding drugs with well-documented activity against pancreatic cancer, and those with relatively high toxicities (i.e. low LD 50 values in mice). Only one of these drugs is FDA approved. We generated dose-response curves to confirm activity and establish IC 50 values for Panc502, Panc410 and another low-passage PDA cell line, Panc486 described below. From these, we selected two drugs because they showed significant variability in their IC50s among the three low passage PDA cell lines (Fig. 3B) Cancer Cell Line Isolating Tools 13 glycoside digitoxin was substantially more toxic to Panc502 than Panc410, while Panc486 had an intermediate sensitivity. We also generated dose response curves using a panel of topoisomerase inhibitors, showing that topoisomerase I inhibitors were generally more effective than topoisomerase II inhibitors (Supplementary Fig. S6 ).
Does in vitro chemosensivity predict in vivo response?
To address the hypothesis that in vitro response could predict in vivo response, we then raised xenografted tumors from Panc410 and Panc502 cell lines, and treated the mice harboring these xenografts with nogalamycin, digitoxin or control for 30 days. We measured the size of tumors twice a week during this time (Fig. 3C) . Both nogalamycin and digitoxin demonstrated more activity against Panc502 than Panc410, supporting the notion that in vitro sensitivity does predict in vivo response, at least with these 2 drugs in these cell lines, as judged by tumor size (Fig. 3C) , weight of the tumors after completing the treatment (Fig. 3D) , and by visual inspection of the residual tumors after treatment ( Supplementary Fig. S7 ).
Isolation of additional cell lines
To test whether we could use this system to routinely generate cell lines from solid cancers, we also isolated a cell line from an ovarian cancer, another highly lethal cancer. The ovarian cancer cell line, FM108, was established from an existing xenograft ( Supplementary Fig. S8 ). We also isolated an additional cell line from a surgically resected PDA. Panc486 was isolated from a xenograft from a patient with a family history of pancreatic cancer (Supplementary Fig. S9 ). In each case, cell lines were response. We also identified 2 terpenoid drugs with >99% growth inhibition.
In this paper, we describe an alternative strategy to traditional CSRA. In contrast to traditional CSRA, the approach described herein uses: i) pure low-passage human 
recently been validated for one patient with a rare type of pancreatic cancer, acincar-cell carcinoma (20) .
The approach describe herein differs from the xenograft-based approach demonstrated by Hidalgo's group (21, 22) . The advantage of the low-passage cell line approach is that more drugs can be screened under highly controlled conditions. A possible advantage of the xenograft approach is that xenografted tumor response may be more biologically predictive of response in patients. We are eager to test whether lowpassage personalized cell line responses can predict patient response. This may be best tested with a malignancy for which several alternative first-line chemotherapeutic choices are available.
Drugs with activity in vivo may not be limited to those that demonstrate >95% growth inhibition. While digitoxin demonstrated 95.1% growth inhibition in vitro, nogalamycin was chosen in part because it only had 75.4% growth inhibition in vitro.
Finally, it is possible that the drugs identified could be synergistic with those currently in clinical use such as gemcitabine, although this remains to be demonstrated. In the future, the combination of the patient's germline SNPs, somatic mutations, mRNA expression and epigenetic changes in the cancer, may play an increasing role in the choice of chemotherapy. Despite this, one can also imagine a role for functional CSRAs. This is currently being attempted for various cancers (23) (24) (25) (26) , although it is controversial whether this testing is truly predictive of in vivo response (2, 3) . This initial sample took about 8 months from surgical resection to full drug panel testing, however we estimate that, with additional optimization, this testing could be accomplished much shorter time. The shorter time could be achieved by implanting more mice, with additional experience, and 
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Cell lines are useful for many other studies of cancer biology since they: i) can be expanded indefinitely, ii) contain all of the gene mutations present in the patient's primary cancer, iii) can be manipulated in vitro by adding or eliminating genes, iv) can be implanted in mice to test the effects of these manipulations on the ability to form tumors (21, 27) , and v) carry few if any additional genetic changes from the primary cancer (28) . Cancer cell lines are also important for other in vitro functional studies, molecular imaging, and possibly isogenic cancer vaccine production. With increasingly powerful tools such as whole genome DNA sequencing, RNAi libraries, and highthroughput drug screens, one can anticipate that the need for cell lines from human cancers will likely increase (13, (29) (30) (31) .
We envision several applications of this system for cancer cell line production.
First, there are no cell lines representing some malignancies, such as oligodendrogliomas and pheochromocytomas, and in others, such as esophageal, thyroid, and salivary gland tumors, many cell lines are contaminants (32) . For others, such as prostate, ovarian and breast cancers, the number of available cell lines cannot fully represent the full spectrum of disease (e.g. most existing prostate cancer cell lines are hormone refractory).
Additionally, some cancers contain unique genetic defects, and successful cell line production is essential to identify pathway members, and perhaps most importantly, for high-throughput drug screening. 
